ReviewResearch and practice in thrombosis and haemostasis2022
Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants.
Review in Research and practice in thrombosis and haemostasis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- Coagulation Profile of Convalescent Plasma Donors and Recipients.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisTrial
- Antiphospholipid syndrome: epidemiology and outcomes in the evolving criteria era.Nature reviews. Rheumatology · 2026Review
- Design and Implementation of an Automated Interpretation Algorithm for Lupus Anticoagulant Functional Testing.International journal of laboratory hematology · 2026Article
- Usefulness and Limits of DOAC Removal Agents Based on Activated Charcoal in Thrombophilia Testing: Literature Review and Expert Proposals.Thrombosis and haemostasis · 2026Review
- Catastrophic Antiphospholipid Syndrome in a Young Female Complicated by Systemic Lupus Erythematosus and Left Atrial Myxoma: A Rare Case Report.Clinical case reports · 2026Article
- Detection of Diagnostic Antibodies in Immune-Mediated Diseases: A Focus on Antigens and Technologies.Chembiochem : a European journal of chemical biology · 2026Review
- Laboratory practice on detection of antiphospholipid antibodies: UK NEQAS blood coagulation survey-2024.British journal of haematology · 2025Article
- Lupus Anticoagulant Testing for Diagnosis of Antiphospholipid Syndrome: A Perspective Informed by Local Practice.Journal of clinical medicine · 2025Article
- Lupus anticoagulant and antiprothrombin antibodies: embracing the future.Journal of thrombosis and haemostasis : JTH · 2025Review
- Update on the Laboratory Diagnosis of Lupus Anticoagulant: Current Challenges and Clinical Involvement.Journal of clinical medicine · 2025Review
- The New Occurrence of Antiphospholipid Syndrome in Severe COVID-19 Cases with Pneumonia and Vascular Thrombosis Could Explain the Post-COVID Syndrome.Biomedicines · 2025Article
- Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent.The American journal of case reports · 2025Article
- Innovative Diagnostic Solutions in Hemostasis.Diagnostics (Basel, Switzerland) · 2024Review
- Multifocal Renal Infarction and Diabetic Ketoacidosis: Diagnostic Challenges and Anticoagulation Management in a Complex Case.The American journal of case reports · 2024Article
- Cytomegalovirus infection associated with livedo reticularis, erythromelalgia, and superficial venous thrombosis.JAAD case reports · 2024Article
- Ischemic Stroke as an Initial Manifestation of Antiphospholipid Syndrome in an Adolescent: A Case Report.Cureus · 2024Article
- Testing for the lupus anticoagulant: the good, the bad, and the ugly.Research and practice in thrombosis and haemostasis · 2024Article
- Simplified Method for Removing Direct Oral Anticoagulant Interference in Mechanical Coagulation Test Systems-A Proof of Concept.Journal of clinical medicine · 2024Article
- The Performance of 2023 American College of Rheumatology (ACR) / European Alliance of Associations for Rheumatology (EULAR) Antiphospholipid Syndrome Classification Criteria in a Real-World Rheumatology Department.Mediterranean journal of hematology and infectious diseases · 2024Article
- Antiphospholipid Antibodies and Vascular Thrombosis in Patients with Severe Forms of COVID-19.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lupus anticoagulants (LA) are one laboratory criterion for classification of antiphospholipid syndrome, with presence of vascular thrombosis and/or pregnancy/fetal morbidity being clinical criteria. The presence of LA is detected (or excluded) by laboratory testing, with the activated partial thromboplastin time and dilute Russell's viper venom time the most commonly used tests. Given the association of thrombosis with LA, it is no surprise that anticoagulants are used to treat or manage such patients. Objectives: To review and discuss interferences from anticoagulants on LA testing, and strategies to mitigate these. Methods: This narrative review assessed interference from commonly used anticoagulants, focusing on LA testing while on direct oral anticoagulants (DOACs), including use of DOAC neutralizers. Results: The classical anticoagulants comprise vitamin K antagonists such as warfarin, and heparins, predominantly unfractionated heparin and low molecular weight heparin (LMWH). DOACs have emerged with favorable efficacy and safety. These comprise two classes: direct anti-thrombin (anti-IIa; dabigatran) or direct anti-Xa (rivaroxaban, apixaban, edoxaban) agents. All anticoagulants affect clotting assays, although there are differences in effects according to anticoagulant and assay. Nevertheless, because of such interferences, anticoagulants can lead to false-negative or false-positive LA findings. Several strategies can mitigate such interferences, including avoidance of testing while patients are on such anticoagulants, temporarily switching to an anticoagulant (i.e., LMWH) with less assay interference, testing for LA at nadir levels of anticoagulants, and/or use of anticoagulant neutralizers. Conclusion: Whilst the best approach is to avoid LA testing on patients taking anticoagulants; if unavoidable, testing may be facilitated by various mitigating strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.